<DOC>
	<DOCNO>NCT00324363</DOCNO>
	<brief_summary>This study design compare effect twice-daily exenatide plus oral antidiabetic ( OAD ) agents twice-daily placebo plus OAD respect glycemic control .</brief_summary>
	<brief_title>Safety Efficacy Exenatide Patients With Type 2 Diabetes Using Metformin Sulfonylureas Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Treated stable dose one follow least 3 month prior screen : * &gt; =1000 mg/day immediaterelease metformin ; metformin &gt; =1000 mg/day sulfonylurea ; sulfonylurea/metformin combination therapy . HbA1c 7.1 % 11.0 % , inclusive . Body Mass Index ( BMI ) &gt; 21 kg/m^2 &lt; 35 kg/m^2 . Have participate study previously , study use exenatide GLP1 analog . Have participate interventional , medical , surgical , pharmaceutical study within 30 day screen . Have characteristic contraindicate metformin sulfonylurea use . Have treat exogenous insulin 1 week within 3 month prior screen . Have use drug weight loss within 1 month screening .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>China</keyword>
</DOC>